Clarithromycin in acute streptococcal tonsillopharyngitis

Main Article Content

Hugo Trujillo
Jaime A. Robledo
María A. Pérez
Rogelio Londoño
María P. Posada
Gloria I. Mejía
Marta C. Tamayo
Jaime A. López

Abstract

Forty patients 10 years of age or older with acute Group A streptococcal pharingotonsillitis were treated with the new macrolide Clarithromycin 250 mg bid for 10 days. Minimal Inhibitory concentration to Clarithromycin varied from 0.06 mcg /mI to 0.5 mcg / ml. The clinical cure rate was 97%; 3% presented improvement. The bacteriologic cure rate was 92.5%. Mild adverse reactions were observed In 6 patients. In conclusion Clarithromycin Is an effective and well tolerated drug for Group A streptococcal pharingotonsllitis.

Keywords:
Streptococcus pyogenes, acute tonsillitis, acute pharyngitis, clarithromycin

Article Details

Author Biographies

Hugo Trujillo, Hospital Pablo Tobon Uribe

Pediatric Infectologist. Pediatrician at the Pablo Tobón Uribe Hospital (HPTU). Researcher and Head of the bacteriology section of the Corporation for Biological Research (CIB), Medellín.

Jaime A. Robledo, Corporación para Investigaciones Biológicas

Physician, Microbiologist - Parasitologist. Researcher in the bacteriology section of the CIB.

María A. Pérez, Pontifical Bolivarian University

Pediatrician, University Welfare, Universidad Pontificia Bolivariana (UPB), Medellín.

Rogelio Londoño, University of Antioquia

Pediatrician. Professor of Pediatrics, University of Antioquia. (U of A).

María P. Posada, Metropolitan Police

Medical, Metropolitan Police, Medellín.

Gloria I. Mejía, Corporación para Investigaciones Biológicas

Bacteriologist CIB.

Marta C. Tamayo, Corporación para Investigaciones Biológicas

Bacteriologist CIB.

Jaime A. López, Pontifical Bolivarian University

Doctor, resident of Microbiology - Parasitology, UPB.

References

Most read articles by the same author(s)

<< < 1 2